CODS - Journal of Dentistry

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 13 , ISSUE 1 ( January-June, 2021 ) > List of Articles

ORIGINAL RESEARCH

Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma

Khadijeh Abdal, Samira Mostafazadeh, Nastaran Ghorbani

Keywords : CD 44, E-cadherin, Leukoplakia, Lichen planus, SCC

Citation Information : Abdal K, Mostafazadeh S, Ghorbani N. Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma. CODS J Dent 2021; 13 (1):6-10.

DOI: 10.5005/jp-journals-10063-0080

License: CC BY-NC 4.0

Published Online: 27-12-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Background: Lichen planus and leukoplakia may change dysplastically over time and are considered as premalignant lesions. CD44 and E-cadherin markers appear to have high potential in the premalignant evaluation of oral leukoplakia and lichen planus lesions. Therefore, the aim of this research was to compare the expression of CD44 and E-cadherin markers in oral leukoplakia and lichen planus and oral squamous cell carcinoma. Materials and methods: This analytical-descriptive research was conducted on 60 blocks of lichen planus, leukoplakia, and squamous cell carcinoma. The blocks were stained by CD44 and E-cadherin antibodies. The data obtained from this research were evaluated by SPSS 22. Results: Only 30% of squamous cell carcinoma (SCC) samples expressed CD44 marker, while 40% and 50% of leukoplakia and lichen planus samples expressed CD44 marker. The expression of E- cadherin marker in SCC samples was 40% in the range of staining, while it was 50% and 60%, respectively in leukoplakia and lichen planus. The intensity of staining was estimated to be equally severe in leukoplakia and lichen planus samples, and there was not a significant difference between the staining intensity of CD44 and E-cadherin (p < 0.16). While in SCC, 70% of the cases showed mild to moderate expression intensity, while was statistically significant compared to lichen planus and leukoplakia (p < 0.004). Conclusion: It seems that the severity of CD44 and E-cadherin incidence can indicate the changes in dysplasia and pre-malignancy of oral lichen planus and leukoplakia associated with oral carcinomas.

HTML PDF Share
  1. MoradzadehKhiavi M, Anvari E, Hamishehkar H, et al. Assessment of the blood parameters, cardiac and liver enzymes in oral squamous cell carcinoma following treated with injectable doxorubicin-loaded nano-particles. Asian Pac J Cancer Prev 2019;20(7):1973–1977. DOI: 10.31557/apjcp.2019.20.7.1973
  2. Seif S, Jafari-ashkavandi Z, Mardani M, et al. Evaluation of serum vitamin d level in oral lichen planuspatients. J Mash Dent Sch 2018;42(1):58–49.
  3. Kalbasi GN, Afshar MN, Dehghan DH, et al. Relationship between E-cadherin protein expression and oral squamous cell carcinoma. Grading 2019;15(3):273–282.
  4. Asareh F, Shirvani S. Immunohistochemical expression of CD44 in erosive lichen planus, epithelial dysplasia, and oral squamous cell carcinoma. J Mash Dent Sch 2018;42(1):66–59.
  5. Khiavi MM, Abdal K, Abbasi MM, et al. Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oralsquamous cell carcinoma in rats. Indian J Med Res 2017;145:112–117. DOI: 10.4103/ijmr.IJMR_542_14
  6. Fakhry C, Lacchetti C, Rooper LM, et al. Papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the college of American pathologists guideline. J Clin Oncol 2018;36(31):3152–3161. DOI: 10.1200/JCO.18.00684
  7. Lewis Jr. JS, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the college of American pathologists. Arch Pathol Lab Med 2018;142(5):559–597. DOI: 10.5858/arpa.2017-0286-CP
  8. Sridevi U, Jain A, Nagalaxmi V, et al. Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in oral carcinomas. Eur J Dent 2015;9(3):364–372. DOI: 10.4103/1305-7456.163238
  9. Mostafazadeh S, Emamverdizadeh P, Abdal K, et al. A comparative study of the frequency of myofibroblasts and macrophages between the oral and cutaneous squamous cell carcinoma. J Dent Res Dent Clin Dent Prospects 2019;13(4): 253–257. DOI: 10.15171/joddd.2019.039
  10. Mello FW, Miguel AFP, Dutra KL, et al. Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis. J Oral Pathol 2018;47(7):633–640. DOI: 10.1111/jop.12726
  11. Van der Waal I. Oral leukoplakia, the ongoing discussion on definition and terminology. Med Oral Patol Oral Cir Bucal 2015;20(6):e685. DOI: 10.4317/medoral.21007
  12. Arduino PG, Bagan J, El-Naggar AK, et al. Urban legends series: oral leukoplakia. Oral Dis 2013;19(7):642–459. DOI: 10.1111/odi.12065
  13. Anderson A, Ishak N. Marked variation in malignant transformation rates of oral leukoplakia. Evid Based Dent 2015;16(4):102–103. DOI: 10.1038/sj.ebd.6401128
  14. Van der Waal I. Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal 2014;19(4):e386. DOI: 10.4317/medoral.20205
  15. Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125(6):612–627. DOI: 10.1016/j.oooo.2017.12.011
  16. Fonseca-Silva T, Diniz MG, de Sousa SF, et al. Association between histopathological features of dysplasia in oral leukoplakia and loss of heterozygosity. Histopathology 2016;68(3):456–460. DOI: 10.13039/501100003593
  17. Zargaran M, Baghaei F, Moghimbeigi A. Comparative study of β-catenin and CD44 immunoexpression in oral lichen planus and squamous cell carcinoma. Int J Dermatol 2018;57(7):794–798. DOI: 10.1111/ijd.14007
  18. Neppelberg E, Loro LL, Oijordsbakken G, et al. Altered CD40 and E-cadherin expression–putative role in oral lichen planus. J Oral Pathol Med 2007;36(3):153–160. DOI: 10.1111/j.1600-0714.2007.00511.x
  19. Chaiyarit P, Thongprasom K, Satayut S, et al. Alteration of the exoression of CD44 isoform in oral epithelial and saliva from patient with oral lichen planus. J Clin Immunol 2008;28(1):26–34. DOI: 10.1007/s10875-007-9128-5
  20. Du Y, Li H. Expression of E-cadherin in oral lichen planus. Exp Ther Med 2015;10(4):1544–1548. DOI: 10.3892/etm.2015.2654
  21. Bahar R, Kunishi M, Kayada Y, et al. CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues. Int J Oral Maxillofac Surg 1997;26(6):443–446. DOI: 10.1016/s0901-5027(97)80010-0
  22. Simionescu C, Mărgăritescu CL, Surpăţeanu M, et al. The study of E-cadherine and CD44 immunoexpression in oral squamous cell carcinoma. Rom J Morphol Embryol 2008;49(2):189–193.
  23. Dalley AJ, Abdul Majeed AA, Pitty LP, et al. LGR5 expression in oral epithelial dysplasia and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119(4):436–440. DOI: 10.1016/j.oooo.2014.11.014
  24. Mannelli G, Magnelli L, Deganello A, et al. Detection of putative stem cell markers, CD44/CD133, in primary and lymph node metastases in head and neck squamous cell carcinomas. A preliminary immunohistochemical and in vitro study. Clin Otolaryngol 2015;40(4):312–320. DOI: 10.1111/coa.12368
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.